Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Sanofi Plavix Sales Triple In U.S.; Avapro Doubles

Executive Summary

Sanofi-Synthelabo is planning an aggressive clinical trial program to expand labeling for its pair of cardiovascular products co-promoted with Bristol-Myers Squibb in the U.S., Plavix and Avapro.

You may also be interested in...



Sanofi-Synthelabo Xaliproden ALS Trial Analysis Begins

Two Phase III trials of xaliproden for treatment of amylotrophic lateral sclerosis have been completed and are being analyzed, Sanofi-Synthelabo Exec VP-Scientific Affairs Gerard Le Fur announced at an analysts briefing in London Feb. 23.

Sanofi-Synthelabo Xaliproden ALS Trial Analysis Begins

Two Phase III trials of xaliproden for treatment of amylotrophic lateral sclerosis have been completed and are being analyzed, Sanofi-Synthelabo Exec VP-Scientific Affairs Gerard Le Fur announced at an analysts briefing in London Feb. 23.

Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program

Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel